Pace begins trials of cardiac diagnostic
This article was originally published in Clinica
Canadian diagnostic manufacturer Pace is beginning trials of an ELISA to measure glycogen phosphorylase (GPBB) this month. The earliest known marker detectable in blood following ischaemic damage, GPBB indicates acute myocardial infarction or unstable angina. Patients are being enrolled at three hospitals - one in Canada and two in the US. Pace plans to file a 510(k) for the laboratory test with the US FDA in April.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.